Background: The prompt identification of carbapenemases, particularly Klebsiella pneumoniae carbapenemases (KPC) and Metallo-β-lactamase (MBL) produced by Klebsiella pneumoniae and Enterobacteriaceae, is imperative in stemming the spread of pathogens carrying these antibiotic-resistant attributes. This retrospective study seeks to delve into the clinical and microbiological characteristics of patients affected by gram-negative bacteria producing KPC and MBL, shedding light on their profiles and impacts. Methods: We analyzed 147 clinical isolates from tertiary care hospitals in Dhaka, Bangladesh. Bacterial identification and Minimum inhibitory concentration (MIC) analysis were performed using conventional culture and VITEK®2 compact system. Carbapenem non-susceptibility (Cns) was defined as a minimum inhibitory concentration (MIC) of >=1 µg/ml for Enterobacteriaceae while Pseudomonasaeruginosa and Acinetobacter baumannii bacterial isolates Imipenem non-susceptibility was defined as an MIC of >=2 µg/ml. Detection of KPC and MBL-producing isolates was performed using the disk potentiation test (DPT) method. Results: All 147 clinical bacterial isolates demonstrated resistance to Imipenem (MIC, 1 to >=16 µg/ml), with Klebsiella pneumoniae carbapenemase (KPC) detected in 26.53 % (39 out of 147) isolates and metallo-beta-lactamases (MBL) in 44.89% (66 out of 147) isolates. Carbapenem resistance was notably prevalent among older male patients of the “> 60” age group, with the ICU harboring the highest number of resistant isolates, primarily associated with Acinetobacter baumannii followed by Klebsiella pneumoniae. Conclusion: Our findings unveiled a concerning prevalence of carbapenem resistance among clinical bacterial isolates, with notable proportions of KPC and MBL producers. The findings underscore the urgent need for effective surveillance and infection control measures to mitigate the spread of multidrug-resistant pathogens in healthcare settings.

The authors have declared no competing interest.

The author(s) received no specific funding for this work.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Not Applicable

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This research works was approved by the “Research and Ethical Practice Committee” of Evercare Hospital, Dhaka, Bangladesh

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Not Applicable

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Not Applicable

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Not Applicable

All data generated or analyzed during this study are included in this published article